There are many protocols available for treating poisonous snake bites and every treating physician thinks that he is always right. We submit a prospective study done over a period of seven months in a tertiary care hospital in Tamil Nadu. This study emphasizes on low dose ASV as a measure for better clinical response and reducing the morbidity and mortality. Aim of the Study: The aim of the study is to prove that low dose ASV can reduce morbidity and mortality, if the guidelines given by state/ national/ WHO are followed on the basis of individual requirements. Material And Methods: This is a prospective observational study in a tertiary medical care hospital, Dharmapuri, Tamil Nadu, south India, between Jan 2016 to July 2016 with 545 patients all are presented with history of snake bite and285 patients with signs of envenomation exclusion criteria all patients with pre existing renal disease, those who are on drugs like aspirin and clopidogrel, and patients with previous history of bleeding diathesis are excluded from this study Results: Totally we encountered 2295 snake bite patients over a period of 3 years from 2013-2015. Among them, 112 (4.88%) patients died of snake bite related AKI. Average number of ASV vials used per patient ranged from 9.27 to 14.83, thus showing the efficacy of low dose ASV regimen. Conclusion: Our study shows that when the signs and symptoms are carefully and constantly observed, low dose ASV is not inferior to high dose ASV in effectively treating snake bite patients as ASV neutralizes only unbound, free flowing venom.